ES2773105T3 - Forma cristalina de un inhibidor de transcriptasa inversa - Google Patents

Forma cristalina de un inhibidor de transcriptasa inversa Download PDF

Info

Publication number
ES2773105T3
ES2773105T3 ES13840379T ES13840379T ES2773105T3 ES 2773105 T3 ES2773105 T3 ES 2773105T3 ES 13840379 T ES13840379 T ES 13840379T ES 13840379 T ES13840379 T ES 13840379T ES 2773105 T3 ES2773105 T3 ES 2773105T3
Authority
ES
Spain
Prior art keywords
compound
range
oxo
methyl
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13840379T
Other languages
English (en)
Spanish (es)
Inventor
Courtney Maguire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Application granted granted Critical
Publication of ES2773105T3 publication Critical patent/ES2773105T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES13840379T 2012-09-26 2013-09-20 Forma cristalina de un inhibidor de transcriptasa inversa Active ES2773105T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Publications (1)

Publication Number Publication Date
ES2773105T3 true ES2773105T3 (es) 2020-07-09

Family

ID=50388877

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13840379T Active ES2773105T3 (es) 2012-09-26 2013-09-20 Forma cristalina de un inhibidor de transcriptasa inversa

Country Status (9)

Country Link
US (1) US9150539B2 (https=)
EP (1) EP2900240B1 (https=)
JP (2) JP6387349B2 (https=)
CN (2) CN104684557A (https=)
BR (1) BR112015005997A8 (https=)
CA (1) CA2882947A1 (https=)
ES (1) ES2773105T3 (https=)
MX (1) MX362517B (https=)
WO (1) WO2014052171A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930585A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309700B2 (en) * 2004-04-02 2007-12-18 Boehringer Ingelheim International Gmbh Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one
WO2006010545A1 (en) * 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
BRPI0811988B1 (pt) * 2007-05-30 2021-05-25 F. Hoffmann-La Roche Ag Composto intermediário e processo para preparação de triazolonas
CN101952274A (zh) * 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂
SI2924034T1 (sl) * 2010-03-30 2017-05-31 Merck Canada Inc. Farmacevtski sestavek, ki obsega nenukleozidni inhibitor reverzne transkriptaze
EP2558093A4 (en) * 2010-04-08 2013-10-02 Merck Sharp & Dohme PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR

Also Published As

Publication number Publication date
US9150539B2 (en) 2015-10-06
MX362517B (es) 2019-01-21
JP2015531372A (ja) 2015-11-02
CN109384765A (zh) 2019-02-26
US20150232447A1 (en) 2015-08-20
JP2018024683A (ja) 2018-02-15
WO2014052171A1 (en) 2014-04-03
EP2900240B1 (en) 2020-01-08
EP2900240A1 (en) 2015-08-05
BR112015005997A8 (pt) 2023-04-11
EP2900240A4 (en) 2016-07-13
BR112015005997A2 (pt) 2017-07-04
JP6387349B2 (ja) 2018-09-05
CA2882947A1 (en) 2014-04-03
MX2015003767A (es) 2015-07-14
CN104684557A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
DK1910370T3 (en) PYRIDINQUINOLINE SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR
CA2965716C (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
AU2005222391B2 (en) HIV integrase inhibitors
CN110678178B (zh) Mk2抑制剂的形式和组合物
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
CN108026087B (zh) 氨基嘧啶甲酮衍生物的柠檬酸盐
CN110461847A (zh) (S)-7-(1-(丁-2-炔酰基)哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺的结晶形式、其制备及用途
ES2773105T3 (es) Forma cristalina de un inhibidor de transcriptasa inversa
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
AU2019286641A1 (en) Small molecule inhibitors of the JAK family of kinases
CN112867708B (zh) 一种mdm2抑制剂，及其制备方法、药物组合物和应用
JP2024514532A (ja) 大環状アゾロピリジン
CA3048771C (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CN121773096A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的l-赖氨酸盐及其各种形式
CN121646582A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的氨丁三醇盐及其各种形式
KR20210012006A (ko) 5-((5-메틸-2-((3,4,5-트리메틸페닐)아미노)피리미딘-4-일)아미노)-벤조[d]옥사졸-2(3h)-온의 푸마레이트 염
HK40062138B (zh) 一类2-氨基嘧啶类化合物及其药物组合物和用途
HK1259825A1 (en) Synthesis of indazoles
HK1259825B (en) Synthesis of indazoles